Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.86
Bid: 3.42
Ask: 4.30
Change: 0.11 (2.93%)
Spread: 0.88 (25.731%)
Open: 3.75
High: 0.00
Low: 0.00
Prev. Close: 3.75
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TMT Patent Update

20 Mar 2008 12:22

PROTEOME SCIENCES plc PRESS RELEASE TMT‚® Patent Update

20th March, 2008. The Board of Proteome Sciences is pleased to confirm to shareholders that it holds issued, granted and enforceable patents for its TMT‚® technology in the major global jurisdictions, including the US and Europe.

Before grant in Europe, the European TMT‚® patent went through an extensive examination process and was exposed to anonymous `third party observations' at that time. These were dismissed and the patent went through to full grant and issued on 13th June 2007 (EP 1275004).

The Board has noted that an opposition has been lodged at the European Patent Office based largely on the same grounds that were made prior to grant through `third party observations'. We will be submitting a full, robust and thorough, response to the opposition in the same way as during the `third party observations'.

Proteome Sciences plc and its patent counsel are in the process of reviewing the opposition. Their initial view is that the opposition does not raise any grounds of objection that prejudice the validity of the patent. These actions confirm the importance and value of the TMT‚® isobaric tandem mass tags.

This does not in any way affect the existing status of the TMT‚® patent in Europe which is issued and enforceable and the Board believes that any manufacture or use of products using isobaric tandem mass tags that come under the broad scope of the TMT‚® patent may need licences from Proteome Sciences.

It is not expected that this process will have any impact on the rapid growth and demand for isobaric mass tags technology nor should it have any effect on Proteome Sciences' ability to successfully conclude the outlicencing of TMT‚® reagents in the early part of 2008.

Ends

Contact Proteome Sciences plc at www.proteomics.com

Christopher Pearce, Chief Executive Officer

James Malthouse, Finance Director, Proteome Sciences plc

Dr. Ian Pike, Chief Business Officer, Proteome Sciences plc

Tel: +44 (0)1932 865065

Adrian Shaw, IKON Associates

Tel: +44 (0)1483 535102 / +44 (0)797 9900733

Matt Baldwin, COAST Communications

Tel: +44 (0)1233 503200

Shaun Dobson, Landsbanki Securities (UK) Ltd

Tel: +44 (0)207 426 9582

Gareth Price, Landsbanki Securities (UK) Ltd

Tel: +44 (0)207 426 9081

PROTEOME SCIENCES PLC
Date   Source Headline
24th Feb 20147:00 amRNSPlacing
7th Feb 20147:00 amRNSTrading Update
3rd Feb 20144:44 pmRNSHolding(s) in Company
27th Dec 20134:35 pmRNSPrice Monitoring Extension
4th Dec 20137:00 amRNSTrading Update
20th Nov 20137:00 amRNSPatient Stratification Biomarkers for Liver Cancer
6th Nov 20132:51 pmRNSHolding(s) in Company
1st Oct 201310:34 amRNSBlocklisting Interim Review
30th Sep 20137:00 amRNSHalf Yearly Report
18th Sep 20132:00 pmRNSKey Assay Development at HUPO
2nd Sep 201312:12 pmRNSHolding(s) in Company
6th Aug 201312:36 pmRNSIssue of Equity
18th Jul 20137:00 amRNSNew Data Shows CK1d Blocks Tau in AD Model
28th Jun 20131:00 pmRNSAGM Statement
28th Jun 20137:00 amRNSPatent Statement
26th Jun 20139:27 amRNSHolding(s) in Company
12th Jun 20137:00 amRNSMajor technology contract
5th Jun 20134:08 pmRNSAnnual Financial Report
30th May 20137:01 amRNSPreliminary Results
19th Apr 20137:00 amRNSTrading Update
2nd Apr 20137:00 amRNSBlock admission return
18th Mar 20137:00 amRNSDevelopments in Alzheimer's Disease
22nd Jan 20137:00 amRNSTrading Statement
31st Dec 20127:00 amRNSCK1D Update
3rd Dec 201211:06 amRNSHolding(s) in Company
28th Sep 20127:00 amRNSHalf Yearly Report
18th Sep 20124:04 pmRNSBlock Admission Return
18th Sep 20124:01 pmRNSBlock Admission Return
18th Sep 20127:00 amRNSFurther re. University of Geneva Study
20th Aug 20127:00 amRNSRe Agreement
29th Jun 201212:10 pmRNSAGM Statement
7th Jun 20123:10 pmRNSAnnual Financial Report
29th May 20127:00 amRNSFinal Results
30th Apr 20127:00 amRNSTotal Voting Rights
5th Apr 20127:00 amRNSStroke biomarker license to Randox
29th Mar 20125:11 pmRNSBlock Admission Return
28th Mar 20127:00 amRNSCompletion of Alzheimer's Plasma Biomarker Study
19th Mar 201210:00 amRNSEuroHYP EU Grant Award for Stroke
8th Mar 20128:55 amRNSHolding(s) in Company
5th Mar 20127:00 amRNSChange of Adviser
24th Feb 20124:24 pmRNSDirector/PDMR Shareholding
31st Jan 20127:00 amRNSTotal Voting Rights
18th Jan 20127:00 amRNSAdditional Listing
22nd Dec 20117:00 amRNSPromising hits against Alzheimer's Target
24th Nov 20117:00 amRNSNovel In Vitro Assays Developed
8th Nov 20113:39 pmRNSDirector Holdings
7th Oct 20117:00 amRNSBlock Admission Return
30th Sep 20117:00 amRNSInterim Results 2011
11th Aug 20114:35 pmRNSPrice Monitoring Extension
11th Aug 20111:33 pmRNSNotification of Major interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.